| 9428492 |
Secondary alcohol substituted triazoles as PDE10 inhibitors |
Scott D. Kuduk, Vadim Dudkin, Carol A. McVean, Thomas S. Reger, Justin T. Steen |
2016-08-30 |
$102,397,000 |
| 9365562 |
1,3 substituted azetidine PDE10 inhibitors |
Douglas C. Beshore, June J. Kim, Scott D. Kuduk, Carol A. McVean, Thomas S. Reger +1 more |
2016-06-14 |
$59,713,000 |
| 9266881 |
Triazolopyridinone PDE10 inhibitors |
James C. Barrow, Mark B. Nolt, William D. Shipe |
2016-02-23 |
$104,084,000 |
| 9200001 |
Triazolyl PDE10 inhibitors |
Vadim Dudkin, June J. Kim, Scott D. Kuduk, Carol A. McVean, Thomas S. Reger +2 more |
2015-12-01 |
$65,660,000 |
| 9062059 |
Pyrimidine PDE10 inhibitors |
Vadim Dudkin, Jeffrey Kern, Mark E. Layton, Izzat T. Raheem |
2015-06-23 |
$67,157,000 |
| 8975261 |
Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors |
Michael J. Breslin, Timothy J. Hartingh, Joseph E. Pero, Izzat T. Raheem, Michael A. Rossi +1 more |
2015-03-10 |
$87,534,000 |
| 8957077 |
Pyrazolopyrimidine PDE 10 inhibitors |
Izzat T. Raheem, John D. Schreier |
2015-02-17 |
$104,696,000 |
| 8846000 |
Radiolabeled PDE10 inhibitors |
Broc A. Flores, Eric Hostetler, Hong Fan |
2014-09-30 |
$59,576,000 |
| 8785467 |
Alkoxy pyrimidine PDE10 inhibitors |
Izzat T. Raheem, William D. Shipe, Cory R. Theberge |
2014-07-22 |
$76,229,000 |
| 8710076 |
2,5-disubstituted piperidine orexin receptor antagonists |
Michael J. Breslin, Paul J. Coleman, Izzat T. Raheem, Anthony J. Roecker, John D. Schreier |
2014-04-29 |
$93,575,000 |
| 8703770 |
Pyridazine carboxamide orexin receptor antagonists |
Paul J. Coleman, Swati P. Mercer, Anthony J. Roecker, John D. Schreier |
2014-04-22 |
$83,770,000 |
| 8691827 |
Amino tetrahydro-pyridopyrimidine PDE10 inhibitors |
Michael J. Breslin, Paul J. Coleman, Izzat T. Raheem, John D. Schreier |
2014-04-08 |
$55,924,000 |
| 8685961 |
Diazepan orexin receptor antagonists |
Karen M. Brashear, Paul J. Coleman, Anthony M. Smith, David B. Whitman |
2014-04-01 |
$62,211,000 |
| 8669272 |
2,5-disubstituted piperidine orexin receptor antagonists |
Michael J. Breslin, Paul J. Coleman, John D. Schreier, David B. Whitman |
2014-03-11 |
$164,805,000 |
| 8618102 |
Bridged diazepan orexin receptor antagonists |
Paul J. Coleman, Georgia B. McGaughey, Anthony J. Roecker, John D. Schreier |
2013-12-31 |
$40,993,000 |
| 8569311 |
Pyridyl piperidine orexin receptor antagonists |
Michael J. Breslin, Paul J. Coleman, John D. Schreier |
2013-10-29 |
$46,137,000 |
| 8492392 |
Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors |
Michael J. Breslin, Paul J. Coleman, Izzat T. Raheem, John D. Schreier |
2013-07-23 |
$117,820,000 |
| 8466281 |
2,5-disubstituted morpholine orexin receptor antagonists |
Paul J. Coleman, Broc A. Flores, John D. Schreier |
2013-06-18 |
$99,229,000 |
| 8389720 |
Quinolone neuropeptide S receptor antagonists |
James C. Barrow, Mark T. Bilodeau, John C. Hartnett, Nathan R. Kett, Yiwei Li +5 more |
2013-03-05 |
$77,218,000 |
| 8362009 |
Substituted diazepan orexin receptor antagonists |
Jeffrey M. Bergman, Paul J. Coleman, Anthony J. Roecker |
2013-01-29 |
$43,785,000 |
| 8357709 |
2,4-disubstituted pyrrolidine orexin receptor antagonists |
Paul J. Coleman, John D. Schreier |
2013-01-22 |
$115,040,000 |
| 8357700 |
2,3-disubstituted piperidine orexin receptor antagonists |
Broc A. Flores, John D. Schreier |
2013-01-22 |
$115,040,000 |
| 8349830 |
Aryl aminopyridine PDE10 inhibitors |
Michael J. Breslin, Izzat T. Raheem |
2013-01-08 |
$59,014,000 |
| 8263586 |
OXO bridged diazepan orexin receptor antagonists |
David B. Whitman |
2012-09-11 |
$64,188,000 |
| 7951797 |
Substituted diazepan orexin receptor antagonists |
Michael J. Breslin, Paul J. Coleman |
2011-05-31 |
$84,401,000 |
